Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
Combined modality approach using Obitunuzumab and involved site low dose irradiation in early
stage nodal follicular lymphoma. Radiation dose will be adapted for low-responders.
Primary Objective:
Evaluation of the rate of metabolic CR after low-dose involved site radiotherapy in
combination with Gazyvaro (Obinutuzumab) in early stage nodal follicular lymphoma in order to
avoid conventional full dose IF radiotherapy.
Secondary Objective:
Efficacy and safety of a response adapted radiation dose treatment schedule.